OpenResearchAlpha

Blood · 19 Nov 2026

Measurable residual disease–dependent unfavorable outcomes in pediatric PAX5 -rearranged B-acute lymphoblastic leukemia

Nicolò Peccatorih-index 3, Alessia Curto, Daniela Silvestri, Stefano Rebellato, Željko Antić, Karin Nebral, Anke K. Bergmann, Sabine Strehl, Martin Zimmermann, Claudia Saitta, Chiara Palmi, Michela Bardini, Sanil Bhatia, Arndt Borkhardt, Manuel Quadri, Daniela Guardo, Luca Lo Nigro, Rosanna Parasole, Maria Caterina Putti, Franco Locatelli, Julia Alten, Martin Stanulla, Barbara Buldini, Jolanda Sarno, Kara L. Davis, Valentino Conter, Adriana Balduzzi, Maria Grazia Valsecchi, Andrea Biondi, Andishe Attarbaschi, Martin Schrappe, Gunnar Cario, Carmelo Rizzari, Giovanni Cazzaniga, Grazia Fazioh-index 25

1
Citations
Crossref's count; others 0–1
0
Citations in 2026
so far
25
Leading author's h-index
Grazia Fazio, in QAI's scholar index
56
References
works it cites, from open citation data

Citations by database

Each database indexes a different set of journals, preprints and books, so they are shown side by side rather than blended.

  • Crossref1
  • OpenAlex1
  • OpenCitations0

Citations per year

The current year is still counting.

  • 2026 so far0

Abstract

Abstract PAX5-altered acute lymphoblastic leukemia (PAX5-alt ALL) is a recently recognized molecular subtype of B-ALL characterized by a distinct transcriptional signature and frequent PAX5 fusions (PAX5-r). Although PAX5-alt ALL is associated with intermediate outcomes, clinical data specifically investigating pediatric PAX5-r ALL remain limited. We analyzed 159 pediatric patients with PAX5-r ALL treated between 2001 and 2024 in Associazione Italiana di Ematologia Oncologia Pediatrica–Berlin-Frankfurt-Münster (AIEOP-BFM) ALL studies across Italy, Germany, and Austria, revealing high-risk (HR) clinical features. Comparative analyses of patients consecutively enrolled in the AIEOP-BFM ALL 2017 study (PAX5-r, n = 96, vs non-PAX5-r, n = 1948) confirmed higher rates of hyperleukocytosis at diagnosis (22.9% vs 8%; P< .001) and enrichment of IKZF1plus profile (14.7% vs 7.8%; P = .0015) in patients with PAX5-r. No relevant differences in terms of minimal/measurable residual disease (MRD)–based treatment response and risk-group stratification were observed. Patients with PAX5-r had a 4-year event-free survival (EFS) and overall survival of 72.6% ± 5.7% and 95.4% ± 2.3%, respectively. Four-year EFS were 100%, 63.4% ± 9.7%, and 63.3% ± 10% for standard-risk, medium-risk (MR), and HR groups, respectively, indicating that the poor prognostic impact of PAX5-r applies only when end-of-induction MRD is positive (MR/HR). Whole-transcriptome sequencing revealed high FLT3 median expression in PAX5-r ALL, and high-throughput drug screening of patient-derived xenografts (PDXs) showed marked sensitivity to several FLT3 inhibitors. Gilteritinib showed potent ex vivo cytotoxicity and synergism with dexamethasone in PAX5-r PDX models. Collectively, this study investigated clinical and biological features of pediatric PAX5-r ALL, highlighting its unfavorable, MRD-dependent prognosis and identifying FLT3 overexpression as a novel, potential therapeutic target.

What the data shows

  • Crossref counts 1 citations, the most of the databases. The others count 0 to 1.
  • Grazia Fazio has the highest h-index among the authors (25).

Graph

This paper in the middle, its authors and their most-cited papers below, the papers it cites to the left and the papers citing it to the right. The timeline lays every paper out by year.

Citing paper shares an authorAuthor without a profileSize shows citations, or h-index for authors

Select a node for its details. Drag to pan, scroll to zoom, drag a node to move it.

Start with

Authors (35)

Each author's standing in QAI's scholar index: the works their ORCID iD is attached to, and for anyone whose ORCID record names a lab OpenResearch follows, their arXiv preprints matched by name and a shared co-author. Names are as printed on the paper.

ProfileMost-cited paper

Cited by 0 papers

Who cites this paper, from open citation data, with Crossref's record of each; the 100 newest when there are more.

0 shown
No citing papers for this filter.

References (56)

What it cites, from open citation data, with Crossref's record of each.

Sign in to see 36 more references

A free account opens the rest of the citing papers and references on every paper’s page.

Measurable residual disease–dependent unfavorable outcomes in pediatric PAX5 -rearranged B-acute lymphoblastic leukemia - QAI OpenResearch